Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

GlaxoSmithKline Recalls Drug Made in Nebraska

By Pharmaceutical Processing | March 1, 2012

LINCOLN, Neb. (AP) — GSK is recalling nearly 400,000 bottles of a blood pressure drug that was packaged in Nebraska.

The Lincoln Journal Star reports (http://bit.ly/zlfbf9 ) that GlaxoSmithKline initiated a recall of the drug DynaCirc CR, which was made at the Novartis plant east of Lincoln.

Novartis manufactured the generic drug on a contract basis at the Lincoln site.

GlaxoSmithKline said in a statement it has received no complaints about contamination or tablet mix-ups. But the company cited a Food and Drug Administration report that found “compliance concerns” related to line clearance during the plant’s packaging process.

The GlaxoSmithKline action is the second recall of drugs at the site this year. Novartis recalled several of its over-the-counter medicines in January, including Excedrin, Bufferin, GasX and NoDoz.

The following day, the FDA warned that pain medications Novartis manufactured in Lincoln for Endo Pharmaceuticals could have been contaminated with other products. But the FDA stopped short of ordering the drugs recalled.

Novartis shut down manufacturing at the Lincoln plant in mid-December after several scathing inspection reports from the FDA.

The FDA documented numerous repeat violations, including the failure to investigate consumer complaints and poor quality-control procedures that allowed some medicines produced there to become contaminated.

The shutdown already has cost Novartis more than $200 million, and the company has said it does not expect the plant to restart production until the summer.

Despite laying off more than 100 temporary workers, the company has kept all of the more than 600 permanent employees working during the shutdown.

__

Information from: The Lincoln Journal Star, http://journalstar.com/

 

 

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE